Simple Summary Hepatocellular carcinoma (HCC) is the most common primary liver cancer,
comprising 90% of liver cancer cases worldwide, with a five-year survival rate of less than …

Simple Summary The incidence of liver cancer is rising globally and is estimated to reach> 1
million cases by 2025. Hepatocellular carcinoma (HCC) accounts for~ 90% of the cases of …

Objectives Splenic volume (SV) was proposed as a relevant prognostic factor for patients
with hepatocellular carcinoma (HCC). We trained a deep-learning algorithm to fully …

Simple Summary The novel CRP–albumin–lymphocyte (CALLY) index has been identified
as a highly predictive tool for stratification of patients with hepatocellular carcinoma (HCC) …

For patients diagnosed with advanced and unresectable hepatocellular carcinoma (HCC),
liver transplantation remains the best option to extend life. Challenges with organ supply …

This study was performed to synthesize a radiopharmaceutical designed for multimodal
hepatocellular carcinoma (HCC) treatment involving radionuclide therapy and magnetic …

Oncolytic bacteria can trigger innate immune activity. However, the antitumour efficacy of
inactivated bacteria is poor, and attenuated live bacteria pose substantial safety risks. Here …

Simple Summary Percutaneous interventional radiological techniques offer many
alternatives for treatment of Hepatocellular Carcinoma (HCC) using local anesthesia and …

Globally, hepatocellular carcinoma (HCC) is the fourth most common cause of death from
cancer. The prevalence of this pathology, which has been on the rise in the last 30 years …

Barcelona clinic liver cancer (BCLC) intermediate stage hepatocellular carcinoma is a
heterogenous disease. Transarterial chemoembolization is offered as the first line therapy in …